Caitong International Asset Management Co., LTD Bei Gene, Ltd. Transaction History
Caitong International Asset Management Co., LTD
- $140 Billion
- Q2 2025
A detailed history of Caitong International Asset Management Co., LTD transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 115 shares of BGNE stock, worth $26,071. This represents 0.02% of its overall portfolio holdings.
Number of Shares
115
Previous 318
63.84%
Holding current value
$26,071
Previous $86.6 Million
67.84%
% of portfolio
0.02%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding BGNE
# of Institutions
269Shares Held
32.2MCall Options Held
113KPut Options Held
106K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion20.22% of portfolio
-
Primecap Management CO Pasadena, CA5.09MShares$1.15 Billion0.94% of portfolio
-
Capital International Investors Los Angeles, CA4.89MShares$1.11 Billion0.2% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million9.68% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.02MShares$231 Million0.03% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...